Results 81 to 90 of about 1,993 (117)

Whole genome and exome sequencing of pancreatic NET to investigate PRRT response

Patients with pancreatic neuroendocrine tumours (PNETs) often have similar baseline clinical characteristics, including grade and molecular imaging phenotype, yet have highly variable responses to peptide receptor radionuclide therapy (PRRT). To identify
William K. Murray, Athena Hatzimihalis, Emma Boehm, Kwang Chin, Richard W. Tothill, Aidan Flynn, Joseph H. A. Vissers, Michael Michael, Annette Hogg, Louise Jackett, Catherine Mitchell, Sean M. Grimmond, Alex Caneborg, Ben Lawrence, Benjamin N.J. Thomson, Owen W. J. Prall, Grace Kong, Kelly Waldeck, Tim Akhurst, Cristin G. Print, Rodney J. Hicks   +20 more
core   +1 more source

Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm

Endocrinology, Diabetes & Metabolism Case Reports
We present a case of recurrent thymic neuroendocrine neoplasm (NEN) in a 43-year-old male, who developed ectopic Cushing syndrome (CS), 8 years after his initial diagnosis.
Monica Majumder, Stephen Clarke, Elizabeth Bernard, Venessa H M Tsang   +3 more
doaj   +1 more source

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours

Endocrine Oncology
Objective: Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth.
Katharina Wang, Christoph J Auernhammer, Simon Lindner, Mathias Zacherl, Rudolf A Werner, Julian Maurer, Lea Peischer, Julia Hamati, Maximilian P Hungbauer, Thomas Knösel, Astrid Reul, Elena Kuzmenko, Diana Vetter, José Oberholzer, Umberto Maccio, Felix Beuschlein, Martin Reincke, Constanze Hantel, Karel Pacak, Ashley B Grossman, Kathrin Zitzmann, Svenja Nölting   +21 more
doaj   +1 more source

Succinate dehydrogenase-related pheochromocytoma and paraganglioma (SDHx-PPGL): clinical and genetic insights from an Indian study

Endocrine Connections
Objective: Data on succinate dehydrogenase-related pheochromocytoma and paraganglioma (SDHx PPGL) in India are limited. We describe the clinical and genetic characteristics of SDHx PPGL from a single center in western India.
Ketki Sunil Ambulkar, Anima Sharma, Vijaya Sarathi, Saba Samad Memon, Anurag Ranjan Lila, Rohit Barnabas, Manjiri Karlekar, Virendra Patil, Samiksha Hegisthe, Gwendolyn Fernandes, Sameer Rege, Gaurav Malhotra, Hemangini Thakkar, Nalini S Shah, Tushar R Bandgar   +14 more
doaj   +1 more source

Review of the Petroleum Resource Rent Tax (PRRT)

1. Successful reforms of oil and gas resource taxation that reclaim the public’s rightful share of resource rents will be vigorously contested with extensive lobbying and campaigning.
Cameron Murray
core   +1 more source

Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center

Endocrine Oncology
Objective: Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (177Lu-DOTATATE) is widely adopted as a later-line treatment (second-line or subsequent therapy) for patients with somatostatin receptor-positive neuroendocrine neoplasm ...
Joao Pedro Thimotheo Batista, Michael De La Iglesia, Hyun Kim, Vikas Prasad, Ravindra Shubha, Rama Suresh, Shuang Wu, Jingxia Liu, Meagan Jacoby, Samuel Urrutia, Nikolaos A Trikalinos   +10 more
doaj   +1 more source

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Journal of Cancer Research and Practice
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT).
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine   +10 more
doaj   +1 more source

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177lu-DOTATATE and 90Y-DOTATOC

, 2009
Purpose: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity.
Bodei, Lisa, Sansovini, Maddalena, Agazzi, Alberto, Pacifici, Monica, De Simone, Michele, Arico, Demetrio, Paganelli, Giovanni, Sierra, Maribel L., Quarna, Jessica, De Cicco, Concetta   +9 more
core   +1 more source

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +1 more source

Significant impact of transient deterioration of renal function on dosimetry in PRRT.

, 2012
Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinically used radiopeptides, is widely used in the management of metastatic neuroendocrine tumors.
Haustermans, Karin, Verbruggen, A., Deroose, Christophe, Mortelmans, L., Mottaghy, F.M., Deroose, C.M., Verslype, Chris, Terwinghe, C., Verbruggen, Alfons, Van Binnebeek, Sofie, Van Cutsem, Eric, Mottaghy, Felix, Mottaghy, Felix M, Deroose, Christophe M., Borbath, I., Haustermans, K., Baete, Kristof, Baete, K., Mortelmans, Luc, Van Binnebeek, S., Vanbilloen, Bert, Terwinghe, Christelle, Borbath, Ivan, Deroose, Christophe M, Vanbilloen, B., Verslype, C., van Cutsem, E.   +26 more
core   +1 more source